Fluorouracil-based combinations in the treatment of metastatic breast cancer

ONCOLOGY

Volumn 12, Issue 1 SUPPL.1, 1998, Pages 31-35

  Klaassen, Ute ^a   Wilke, Hansjochen ^a   Harstrick, Andreas ^a   Seeber, Siegfried ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOTOXICITY; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; FEMALE; HUMAN; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ADULT; AGED; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; FORECASTING; HUMANS; LEUCOVORIN; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL;

EID: 0031916711     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Swain SM, Lippman ME, Egan EF, et al: Fluorouracil and high dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7(7):890-899, 1989.
2. Hansen R, Quebbeman E, Beatty P: Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res Treat 10:145-149, 1987.
3. Jabboury K, Holmes F, Theriault R, et al: Fluorouracil rechallenge by protracted continuous infusion in refractory breast cancer(abstract). Proc Am Soc Clin Oncol 7: 39, 1988.
4. Huan S, Singhakowinta A, Samal B, et al: Efficacy of continuous infusion of low dose 5-FU in previously treated metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 7:37, 1988.
5. Petrelli N, Herrera L, Rustum YM: A prospective randomized trial of 5-fluorouracil vs 5-fluorouracil and high dose leucovorin vs 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559-1565, 1987.
6. Machover D, Goldschmidt E, Chollet P, et al: Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high dose folinic acid. J Clin Oncol 4:685-696, 1986.
7. Doroshow TH, Bertrand M, Multhauf P, et al: Prospective randomized trial comparing 5-FU vs 5-FU and high dose folinic acid for treatment of advanced colorectal cancer (abstract). Proc Am Soc Clin Oncol 6:9, 1987.
8. Erlichrnan C, Fine S, Wong A, et al: A comparison of 5-fluorouracil and folinic acid vs 5-FU in metastatic colorectal carcinoma (abstract). Proc Am Soc Clin Oncol 5:82, 1986.
9. Doroshow JH, Leong L, Margolin K, et al: Refractory metastatic breast cancer: Salvage therapy with fluorouracil and high dose continuous infusion leucovorin calcium. J Clin Oncol 7:439-444, 1989.
10. Houghton JA, Schmidt C, Houghton P, et al: The effect of derivatives of folinic acid on the fluorodeoxyuridylate-thymidilate synthetase covalent complex in human colon xenografts. Eur J Cancer 18:347-354, 1982.
11. Yin MB, Zakrzewski SF, Hakala MT, et al: Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharmacol 23:190-197, 1983.
12. Evans RM, Laskin JD, Hakala MT, et al: Effects of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 41:3288-3295, 1981.
13. Marini G, Simonchini E, Zaniboni A, et al: 5-fluorouracil and high dose folinic acid as salvage treatment of advanced breast cancer: An update Oncology 44 336-340, 1987
14. Fine S, Erlichman C, Kaizer L, et al: Phase II trial of 5-FU and folinic acid as first line treatment for metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 7: 41, 1988.
15. Loprinzi CL: 5-Fluorouracil with leucovorin in breast cancer. Cancer 63: 1045-1047, 1989.
16. Köhne-Wompner CH, Schmoll HJ, Harstrick A, et al: Chemotherapeutic strategies in metastatic colorectal cancer. An overview of current clinical trials. Semin Oncol 19:105-125, 1992.
17. Wilke H, Klaassen U, Achterrath W, et al: Phase I/II study with a weekly 24 hour infusion of 5-fluorouracil plus high dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. Ann Oncol 7(1):55-58, 1996.
18. Henderson IC: Chemotherapy for advanced disease, in: Harris JR, Hellman S, Henderson IC: Breast diseases, pp 428-479 Philadelphia, JB Lippincott, 1987.
19. Rowinsky EK, Donehower RC: Taxol: Twenty years later the story unfolds. J Natl Cancer Inst 83:1778-1781, 1991.
20. Rowinsky EK, Cazenave LA, Donehower RC: Taxol: A novel investigational antineoplastic agent. J Natl Cancer Inst 82:1247-1259, 1990.
21. Rowinsky EK, Onetto N, Canetta RM: Taxol: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 19:646-662, 1992.
22. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991.
23. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993.
24. Seidman AD, Crown JPA, Reichman B: Lack of clinical cross resistance of Taxol with anthracycline in the treatment of metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 12: 53, 1993.
25. Nabholtz JM, Gelmon K, Bontenbal M, et al: Randomized trial of two doses of taxol in metastatic breast cancer: An interim analysis (abstract). Proc Am Soc Clin Oncol 12:42, 1993
26. Yarbro JW, Bornstein MD, Mastrangelo MJ, et al: Newest clinical approaches with paclitaxel (Taxol). Semin Oncol 21(suppl):1-62, 1994.
27. Gianni L, Capri G, Munzone E, et al: Paclitaxel efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin Oncol 21(suppl):29-33 1994.
28. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958.
29. Wilke H, Vanhoefer U, Fink U, et al: Weekly high dose FU/folinic acid and cisplatin: A safe and active combination for advanced gastric cancer (abstract). Second International Conference on Biology, Prevention and Treatment of Gastrointestinal Malignancies, Cologne, January 9-12, 1995
30. Vanhoefer U, Harstrick A, Wilke H, et al: Schedule dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro. Eur J Cancer 31A(1):92-97, 1995.
31. Klaassen U, Wilke H, Phillippou Pari C, et al: Phase I/II study with paclitaxel in combination with weekly high dose 5-fluorouracil/folinic acid (HD-FU/FA) in the treatment of metastatic breast cancer Semin Oncol 22(6;suppl14):7-11, 1995.
32. Aschele C, Sobrero A, Faderan MA, et al: Novel mechanisms of resistance to 5-fIuorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52:1855-1864, 1992.
33. Harstrick A, Gonzales A, Schleucher NA, et al: Human tumor cell lines develop different mechanisms of resistance to 5-fluorouracil when exposed to various schedules of the drug (abstract). Proc Am Assoc Cancer Res 36: 1889, 1995.
34. Sledge J, Loehrer PJ, Roth BJ, et al: Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6:1811-1814, 1988.
35. Evans RM, Laskin JD, Hakala MT: Effects of excess folates and deoxyuridine on the activity and site of action of 5-fluorouracil. Cancer Res 41:3288-3295, 1981.
36. Yin MB, Zakrzewski SF, Hakala MT: Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharmacol 23:190-197, 1983.
37. Keyomarsi K, Moran RG: Folinic acid augmentation of the effects of pluoropyrimidines on murine and human leukemic cells. Cancer Res 46:5229-5235, 1986.
38. Spears CP, Gustavson BG, Berne M, et al: Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res 48: 5894-5900, 1988.
39. Collins J, Dedrick R, King F, et al: Nonlinear pharmacokinetics models for 5-fluorouracil in man: Intravenous and intraperitoneal routes. Clin Pharmacol Ther 28:235-246, 1980.
40. Ensminger WD, Rosowsky A, Raso V, et al: A clinical pharmacologic evaluation of hepatic arterial infusion of 5-fluoro-2-deoxyuridine and 5-fluorouracil. Cancer Res 38:3784-3792, 1978.